Acumen Pharmaceuticals Stock Earnings Reports

Acumen Pharma reported continued progress in Q1 2026 focused on its lead antibody sabirnetug and its next-generation blood-brain barrier (EBD) candidates. The Phase II ALTITUDE-AD trial of sabirnetug remains on track, with high conversion into the 12-month open-label extension and top-line results expected late 2026. ALTITUDE is powered to detect differences on the iADRS primary endpoint after 18 months and will report key secondary endpoints including CDR-SB, ARIA/safety rates, and fluid/imaging biomarkers across two active doses (35 and 50 mg/kg). The EBD program is advancing preclinically; Acumen expects to exercise its option to license two JCR-derived candidates in Q2 2026 and targets an IND filing in mid-2027. Financially, the company ended March 31, 2026 with $128.4M in cash and marketable securities (includes $35.75M private placement supporting the EBD program) and expects this runway to support current activities into early 2027. Q1 R&D and G&A expenses declined vs. prior year, with a net loss of $20.7M. Management emphasized the potential differentiation of an oligomer-targeting approach (vs. plaque-directed therapies) and the potential advantages of EBD carriers for improved brain exposure, safety margin and subcutaneous dosing.